supn-202106300001356576false12-312021Q20.0168545http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent00013565762021-01-012021-06-30xbrli:shares00013565762021-08-02iso4217:USD00013565762021-06-3000013565762020-12-31iso4217:USDxbrli:shares0001356576us-gaap:ProductMember2021-04-012021-06-300001356576us-gaap:ProductMember2020-04-012020-06-300001356576us-gaap:ProductMember2021-01-012021-06-300001356576us-gaap:ProductMember2020-01-012020-06-300001356576us-gaap:RoyaltyMember2021-04-012021-06-300001356576us-gaap:RoyaltyMember2020-04-012020-06-300001356576us-gaap:RoyaltyMember2021-01-012021-06-300001356576us-gaap:RoyaltyMember2020-01-012020-06-3000013565762021-04-012021-06-3000013565762020-04-012020-06-3000013565762020-01-012020-06-300001356576us-gaap:CommonStockMember2020-12-310001356576us-gaap:AdditionalPaidInCapitalMember2020-12-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001356576us-gaap:RetainedEarningsMember2020-12-310001356576us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100013565762021-01-012021-03-310001356576us-gaap:CommonStockMember2021-01-012021-03-310001356576us-gaap:RetainedEarningsMember2021-01-012021-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001356576us-gaap:CommonStockMember2021-03-310001356576us-gaap:AdditionalPaidInCapitalMember2021-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001356576us-gaap:RetainedEarningsMember2021-03-3100013565762021-03-310001356576us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001356576us-gaap:CommonStockMember2021-04-012021-06-300001356576us-gaap:RetainedEarningsMember2021-04-012021-06-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001356576us-gaap:CommonStockMember2021-06-300001356576us-gaap:AdditionalPaidInCapitalMember2021-06-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001356576us-gaap:RetainedEarningsMember2021-06-300001356576us-gaap:CommonStockMember2019-12-310001356576us-gaap:AdditionalPaidInCapitalMember2019-12-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001356576us-gaap:RetainedEarningsMember2019-12-3100013565762019-12-310001356576us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100013565762020-01-012020-03-310001356576us-gaap:CommonStockMember2020-01-012020-03-310001356576us-gaap:RetainedEarningsMember2020-01-012020-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001356576us-gaap:CommonStockMember2020-03-310001356576us-gaap:AdditionalPaidInCapitalMember2020-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001356576us-gaap:RetainedEarningsMember2020-03-3100013565762020-03-310001356576us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001356576us-gaap:CommonStockMember2020-04-012020-06-300001356576us-gaap:RetainedEarningsMember2020-04-012020-06-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001356576us-gaap:CommonStockMember2020-06-300001356576us-gaap:AdditionalPaidInCapitalMember2020-06-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001356576us-gaap:RetainedEarningsMember2020-06-3000013565762020-06-30supn:segment0001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMembersrt:ScenarioPreviouslyReportedMember2020-06-092020-06-090001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-06-090001356576supn:SPN830RegulatoryAndCommercialActivitiesMember2020-06-092020-06-090001356576supn:SPN830FutureSalesPerformanceMember2020-06-092020-06-090001356576supn:SPN830FDAAcceptanceMilestoneMember2020-06-092020-06-090001356576supn:SPN830NDAApprovalMilestoneMember2020-06-092020-06-090001356576supn:SPN830FirstCommercialAndSaleMember2020-06-092020-06-090001356576supn:APOKYNMember2020-06-092020-06-090001356576supn:APOKYNAndSPN830Member2020-06-092020-06-090001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-06-102021-03-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-06-092020-06-090001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-12-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2021-06-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-01-012020-12-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMembersrt:ScenarioPreviouslyReportedMember2020-06-090001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2021-04-012021-06-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-10-012020-12-310001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMemberus-gaap:InProcessResearchAndDevelopmentMembersrt:ScenarioPreviouslyReportedMember2020-06-090001356576us-gaap:DevelopedTechnologyRightsMembersupn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMembersrt:ScenarioPreviouslyReportedMember2020-06-090001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMemberus-gaap:InProcessResearchAndDevelopmentMember2020-06-090001356576us-gaap:DevelopedTechnologyRightsMembersupn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-06-090001356576us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMembersupn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-06-092020-06-090001356576us-gaap:DevelopedTechnologyRightsMembersupn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMembersrt:MaximumMember2020-06-092020-06-090001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-04-012020-06-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2020-01-012020-06-300001356576supn:TrokendiXrMember2021-04-012021-06-300001356576supn:TrokendiXrMember2020-04-012020-06-300001356576supn:TrokendiXrMember2021-01-012021-06-300001356576supn:TrokendiXrMember2020-01-012020-06-300001356576supn:OxtellarXRMember2021-04-012021-06-300001356576supn:OxtellarXRMember2020-04-012020-06-300001356576supn:OxtellarXRMember2021-01-012021-06-300001356576supn:OxtellarXRMember2020-01-012020-06-300001356576supn:APOKYNMember2021-04-012021-06-300001356576supn:APOKYNMember2020-04-012020-06-300001356576supn:APOKYNMember2021-01-012021-06-300001356576supn:APOKYNMember2020-01-012020-06-300001356576supn:MYOBLOCMember2021-04-012021-06-300001356576supn:MYOBLOCMember2020-04-012020-06-300001356576supn:MYOBLOCMember2021-01-012021-06-300001356576supn:MYOBLOCMember2020-01-012020-06-300001356576supn:XADAGOMember2021-04-012021-06-300001356576supn:XADAGOMember2020-04-012020-06-300001356576supn:XADAGOMember2021-01-012021-06-300001356576supn:XADAGOMember2020-01-012020-06-300001356576supn:QelbreeMember2021-04-012021-06-300001356576supn:QelbreeMember2020-04-012020-06-300001356576supn:QelbreeMember2021-01-012021-06-300001356576supn:QelbreeMember2020-01-012020-06-30xbrli:pure0001356576supn:TrokendiXrMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-04-012021-06-300001356576supn:TrokendiXrMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-06-300001356576supn:TrokendiXrMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2020-04-012020-06-300001356576supn:TrokendiXrMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-06-300001356576supn:ThreeMajorCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-06-300001356576supn:ThreeMajorCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-06-300001356576us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMembersupn:NavitorPharmaceuticalsIncMember2020-04-012020-04-300001356576us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMembersupn:NavitorPharmaceuticalsIncMember2020-04-012020-06-300001356576us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMembersupn:NavitorPharmaceuticalsIncMember2021-01-012021-03-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:FairValueInputsLevel2Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:MunicipalBondsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-3100013565762020-01-012020-12-310001356576supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember2021-06-300001356576supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember2020-12-310001356576supn:SalesBasedContingentConsiderationLiabilityMember2021-06-300001356576supn:SalesBasedContingentConsiderationLiabilityMember2020-12-310001356576us-gaap:InProcessResearchAndDevelopmentMember2021-06-300001356576us-gaap:InProcessResearchAndDevelopmentMember2020-12-310001356576us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2021-01-012021-06-300001356576us-gaap:DevelopedTechnologyRightsMembersrt:MaximumMember2021-01-012021-06-300001356576us-gaap:DevelopedTechnologyRightsMember2021-06-300001356576us-gaap:DevelopedTechnologyRightsMember2020-12-310001356576srt:MinimumMembersupn:PatentDefenseCostsMember2021-01-012021-06-300001356576supn:PatentDefenseCostsMembersrt:MaximumMember2021-01-012021-06-300001356576supn:PatentDefenseCostsMember2021-06-300001356576supn:PatentDefenseCostsMember2020-12-310001356576us-gaap:ConvertibleDebtMember2021-06-30supn:day0001356576us-gaap:ConvertibleDebtMembersupn:ConversionCircumstanceOneMember2021-01-012021-06-300001356576us-gaap:ConvertibleDebtMembersupn:ConversionCircumstanceTwoMember2021-01-012021-06-30utr:Rate0001356576us-gaap:ConvertibleDebtMember2021-01-012021-06-300001356576us-gaap:ConvertibleDebtMember2020-12-310001356576us-gaap:ConvertibleNotesPayableMemberus-gaap:FairValueInputsLevel2Member2021-06-300001356576us-gaap:ConvertibleNotesPayableMemberus-gaap:FairValueInputsLevel2Member2020-12-310001356576us-gaap:ConvertibleDebtMember2020-01-012020-12-310001356576us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001356576us-gaap:ResearchAndDevelopmentExpenseMember2020-04-012020-06-300001356576us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001356576us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-04-012021-06-300001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-04-012020-06-300001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-06-300001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-300001356576supn:StockOptionStockAppreciationRightsMember2020-12-310001356576supn:StockOptionStockAppreciationRightsMember2020-01-012020-12-310001356576supn:StockOptionStockAppreciationRightsMember2021-01-012021-06-300001356576supn:StockOptionStockAppreciationRightsMember2021-06-300001356576us-gaap:RestrictedStockUnitsRSUMember2020-12-310001356576us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001356576us-gaap:RestrictedStockUnitsRSUMember2021-06-300001356576supn:PerformanceBasedUnitsMember2020-12-310001356576supn:MarketBasedUnitsMember2020-12-310001356576us-gaap:PerformanceSharesMember2020-12-310001356576supn:PerformanceBasedUnitsMember2021-01-012021-06-300001356576supn:MarketBasedUnitsMember2021-01-012021-06-300001356576us-gaap:PerformanceSharesMember2021-01-012021-06-300001356576supn:PerformanceBasedUnitsMember2021-06-300001356576supn:MarketBasedUnitsMember2021-06-300001356576us-gaap:PerformanceSharesMember2021-06-300001356576us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001356576us-gaap:EmployeeStockOptionMember2020-04-012020-06-300001356576us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001356576us-gaap:EmployeeStockOptionMember2020-01-012020-06-3000013565762019-02-010001356576us-gaap:AccountsReceivableMembersupn:ThreeMajorCustomersMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001356576supn:ProductCandidatesMember2020-12-310001356576supn:ProductCandidatesMember2021-06-300001356576supn:LabEquipmentAndFurnitureMember2021-06-300001356576supn:LabEquipmentAndFurnitureMember2020-12-310001356576us-gaap:LeaseholdImprovementsMember2021-06-300001356576us-gaap:LeaseholdImprovementsMember2020-12-310001356576us-gaap:ComputerSoftwareIntangibleAssetMember2021-06-300001356576us-gaap:ComputerSoftwareIntangibleAssetMember2020-12-310001356576us-gaap:ComputerEquipmentMember2021-06-300001356576us-gaap:ComputerEquipmentMember2020-12-3100013565762014-09-30iso4217:EUR0001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2021-01-012021-06-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2019-03-012019-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One) | | | | | |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2021
OR
| | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 001-35518
SUPERNUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter) | | | | | | | | | | | | |
Delaware | | | | 20-2590184 |
(State or other jurisdiction of incorporation or organization) | | | | (I.R.S. Employer Identification No.) |
| | | | |
9715 Key West Avenue | Rockville | MD | | 20850 |
(Address of principal executive offices) | | | | (Zip Code) |
(301) 838-2500
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒ Yes No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. | | | | | | | | | | | | |
Large accelerated filer | ☒
| | Accelerated filer | ☐ |
| | | | |
Non-accelerated filer | ☐ | | Smaller reporting company | ☐ |
| | | | |
| | | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No
Securities registered pursuant to Section 12(b) of the Exchange Act | | | | | | | | | | | | | | | | | | | | |
Title of each class | | Outstanding at August 2, 2021 | | Trading Symbol | | Name of each exchange on which registered |
Common Stock, $0.001 par value per share | | 53,145,884 | | SUPN | | The Nasdaq Global Market |
SUPERNUS PHARMACEUTICALS, INC.
FORM 10-Q — QUARTERLY REPORT
FOR THE QUARTERLY PERIOD ENDED June 30, 2021
PART I — FINANCIAL INFORMATION
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data) | | | | | | | | | | | |
| June 30, | | December 31, |
| 2021 | | 2020 |
| (unaudited) | | |
Assets | | | |
Current assets | | | |
Cash and cash equivalents | $ | 223,771 | | | $ | 288,640 | |
Marketable securities | 186,070 | | | 133,893 | |
Accounts receivable, net | 137,275 | | | 140,877 | |
Inventories, net | 58,391 | | | 48,325 | |
Prepaid expenses and other current assets | 33,737 | | | 18,682 | |
Total current assets | 639,244 | | | 630,417 | |
Long term marketable securities | 445,473 | | | 350,359 | |
Property and equipment, net | 17,065 | | | 37,824 | |
Intangible assets, net | 352,628 | | | 364,342 | |
Goodwill | 77,963 | | | 77,911 | |
Other assets | 40,687 | | | 43,249 | |
Total assets | $ | 1,573,060 | | | $ | 1,504,102 | |
| | | |
Liabilities and stockholders’ equity | | | |
Current liabilities | | | |
Accounts payable and accrued liabilities | $ | 79,993 | | | $ | 78,934 | |
Accrued product returns and rebates | 173,598 | | | 126,192 | |
Contingent consideration, current portion | 23,540 | | | 30,900 | |
Other current liabilities | 6,316 | | | 9,082 | |
Total current liabilities | 283,447 | | | 245,108 | |
Convertible notes, net | 370,383 | | | 361,751 | |
Contingent consideration, long term | 45,430 | | | 45,800 | |
Operating lease liabilities, long term | 36,143 | | | 28,579 | |
Deferred income tax liabilities | 32,986 | | | 35,215 | |
Other liabilities | 19,092 | | | 42,791 | |
Total liabilities | 787,481 | | | 759,244 | |
| | | |
Stockholders’ equity | | | |
Common stock, $0.001 par value; 130,000,000 shares authorized; 53,144,759 and 52,868,482 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively | 53 | | | 53 | |
Additional paid-in capital | 424,175 | | | 409,332 | |
Accumulated other comprehensive earnings, net of tax | 5,433 | | | 8,975 | |
Retained earnings | 355,918 | | | 326,498 | |
Total stockholders’ equity | 785,579 | | | 744,858 | |
| | | |
Total liabilities and stockholders’ equity | $ | 1,573,060 | | | $ | 1,504,102 | |
See accompanying notes.
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Earnings
(in thousands, except share and per share data)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months ended June 30, | | Six Months ended June 30, |
| 2021 | | 2020 | | 2021 | | 2020 |
| (unaudited) | | (unaudited) |
Revenues | | | | | | | |
Net product sales | $ | 138,628 | | | $ | 123,984 | | | $ | 267,009 | | | $ | 216,474 | |
Royalty revenues | 2,701 | | | 2,745 | | | 5,252 | | | 5,231 | |
Total revenues | 141,329 | | | 126,729 | | | 272,261 | | | 221,705 | |
| | | | | | | |
Costs and expenses | | | | | | | |
Cost of goods sold (a) | 25,028 | | | 8,386 | | | 39,982 | | | 12,538 | |
Research and development | 15,455 | | | 22,247 | | | 49,735 | | | 41,184 | |
Selling, general and administrative | 69,535 | | | 48,103 | | | 130,992 | | | 89,717 | |
Amortization of intangible assets | 5,948 | | | 2,445 | | | 11,955 | | | 3,706 | |
Contingent consideration gain | (8,750) | | | — | | | (7,730) | | | — | |
Total costs and expenses | 107,216 | | | 81,181 | | | 224,934 | | | 147,145 | |
| | | | | | | |
Operating earnings | 34,113 | | | 45,548 | | | 47,327 | | | 74,560 | |
| | | | | | | |
Other income (expense) | | | | | | | |
Interest expense | (5,467) | | | (5,815) | | | (11,564) | | | (11,570) | |
Interest and other income, net | 2,589 | | | 7,477 | | | 6,401 | | | 13,254 | |
Total other income (expense) | (2,878) | | | 1,662 | | | (5,163) | | | 1,684 | |
| | | | | | | |
Earnings before income taxes | 31,235 | | | 47,210 | | | 42,164 | | | 76,244 | |
| | | | | | | |
Income tax expense | 7,509 | | | 12,543 | | | 12,744 | | | 20,059 | |
Net earnings | $ | 23,726 | | | $ | 34,667 | | | $ | 29,420 | | | $ | 56,185 | |
| | | | | | | |
Earnings per share | | | | | | | |
Basic | $ | 0.45 | | | $ | 0.66 | | | $ | 0.56 | | | $ | 1.07 | |
Diluted | $ | 0.43 | | | $ | 0.65 | | | $ | 0.54 | | | $ | 1.05 | |
| | | | | | | |
Weighted-average shares outstanding | | | | | | | |
Basic | 53,005,344 | | | 52,557,035 | | | 52,985,472 | | | 52,545,910 | |
Diluted | 54,724,146 | | | 53,645,828 | | | 54,601,533 | | | 53,611,418 | |
______________________________
(a) Excludes amortization of acquired intangible assets
See accompanying notes.
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Comprehensive Earnings
(in thousands)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months ended June 30, | | Six Months ended June 30, |
| 2021 | | 2020 | | 2021 | | 2020 |
| (unaudited) | | (unaudited) |
Net earnings | $ | 23,726 | | | $ | 34,667 | | | $ | 29,420 | | | $ | 56,185 | |
Other comprehensive earnings | | | | | | | |
Unrealized (loss) gain on marketable securities, net of tax | (816) | | | 11,525 | | | (3,542) | | | 3,942 | |
Other comprehensive (loss) income | (816) | | | 11,525 | | | (3,542) | | | 3,942 | |
| | | | | | | |
Comprehensive earnings | $ | 22,910 | | | $ | 46,192 | | | $ | 25,878 | | | $ | 60,127 | |
See accompanying notes.
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
Six Months ended June 30, 2021 and 2020
(unaudited, in thousands, except share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
j | Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive Earnings (Loss) | | Retained Earnings | | Total Stockholders’ Equity |
| Shares | | Amount | | | | |
Balance, December 31, 2020 | 52,868,482 | | | $ | 53 | | | $ | 409,332 | | | $ | 8,975 | | | $ | 326,498 | | | $ | 744,858 | |
Share-based compensation | — | | | — | | | 4,371 | | | — | | | — | | | 4,371 | |
Issuance of common stock in connection with the Company’s equity award plans | 125,655 | | | — | | | 2,247 | | | — | | | — | | | 2,247 | |
Net earnings | — | | | — | | | — | | | — | | | 5,694 | | | 5,694 | |
Unrealized loss on marketable securities, net of tax | — | | | — | | | — | | | (2,726) | | | — | | | (2,726) | |
Balance, March 31, 2021 | 52,994,137 | | | $ | 53 | | | $ | 415,950 | | | $ | 6,249 | | | $ | 332,192 | | | $ | 754,444 | |
Share-based compensation | — | | | — | | | 5,476 | | | — | | | — | | | 5,476 | |
Issuance of common stock in connection with the Company’s equity award plans | 150,622 | | | — | | | 2,749 | | | — | | | — | | | 2,749 | |
Net earnings | — | | | — | | | — | | | — | | | 23,726 | | | 23,726 | |
Unrealized loss on marketable securities, net of tax | — | | | — | | | — | | | (816) | | | — | | | (816) | |
Balance, June 30, 2021 | 53,144,759 | | | $ | 53 | | | $ | 424,175 | | | $ | 5,433 | | | $ | 355,918 | | | $ | 785,579 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive Earnings (Loss) | | Retained Earnings | | Total Stockholders’ Equity |
| Shares | | Amount | | | | |
Balance, December 31, 2019 | 52,533,348 | | | $ | 53 | | | $ | 388,410 | | | $ | 7,417 | | | $ | 199,548 | | | $ | 595,428 | |
Share-based compensation | — | | | — | | | 3,988 | | | — | | | — | | | 3,988 | |
Issuance of common stock in connection with the Company’s equity award plans | 3,811 | | | — | | | 32 | | | — | | | — | | | 32 | |
Net earnings | — | | | — | | | — | | | — | | | 21,518 | | | 21,518 | |
Unrealized loss on marketable securities, net of tax | — | | | — | | | — | | | (7,583) | | | — | | | (7,583) | |
Balance, March 31, 2020 | 52,537,159 | | | $ | 53 | | | $ | 392,430 | | | $ | (166) | | | $ | 221,066 | | | $ | 613,383 | |
Share-based compensation | — | | | — | | | 4,962 | | | — | | | — | | | 4,962 | |
Issuance of common stock in connection with the Company’s equity award plans | 86,925 | | | — | | | 1,437 | | | — | | | — | | | 1,437 | |
Net earnings | — | | | — | | | — | | | — | | | 34,667 | | | 34,667 | |
Unrealized gain on marketable securities, net of tax | — | | | — | | | — | | | 11,525 | | | — | | | 11,525 | |
Balance, June 30, 2020 | 52,624,084 | | | $ | 53 | | | $ | 398,829 | | | $ | 11,359 | | | $ | 255,733 | | | $ | 665,974 | |
See accompanying notes.
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands) | | | | | | | | | | | |
| Six Months ended June 30, |
| 2021 | | 2020 |
| (unaudited) |
Cash flows from operating activities | | | |
Net earnings | $ | 29,420 | | | $ | 56,185 | |
Adjustments to reconcile net earnings to net cash provided by operating activities: | | | |
Depreciation and amortization | 13,213 | | | 4,778 | |
Navitor investment R&D expense | 15,000 | | | — | |
Amortization of deferred financing costs and debt discount | 8,632 | | | 8,179 | |
Realized gains from sales of marketable securities | (219) | | | (3,316) | |
Amortization of premium/discount on marketable securities | (2,371) | | | 984 | |
Change in fair value of contingent consideration | (7,730) | | | — | |
Other noncash adjustments, net | (651) | | | 359 | |
Share-based compensation expense | 9,847 | | | 8,950 | |
Deferred income tax provision | (2,046) | | | (3,062) | |
Changes in operating assets and liabilities: | | | |
Accounts receivable | 3,605 | | | (20,431) | |
Inventories | (7,950) | | | 1,955 | |
Prepaid expenses and other assets | (18,003) | | | (5,943) | |
Accrued product returns and rebates | 47,406 | | | 28,298 | |
Accounts payable and other liabilities | (5,679) | | | 23,931 | |
Net cash provided by operating activities | 82,474 | | | 100,867 | |
| | | |
Cash flows from investing activities | | | |
Purchases of marketable securities | (233,272) | | | (15,382) | |
Sales and maturities of marketable securities | 83,844 | | | 257,936 | |
Purchases of property and equipment | (1,508) | | | (3,072) | |
Acquisition of USWM, net of cash acquired | (950) | | | (297,200) | |
Deferred legal fees | (453) | | | (24) | |
Investment in Navitor Pharmaceuticals, Inc. | — | | | (15,000) | |
Net cash used in investing activities | (152,339) | | | (72,742) | |
| | | |
Cash flows from financing activities | | | |
Proceeds from issuance of common stock | 4,996 | | | 1,469 | |
Net cash provided by financing activities | 4,996 | | | 1,469 | |
| | | |
Net change in cash and cash equivalents | (64,869) | | | 29,594 | |
Cash and cash equivalents at beginning of year | 288,640 | | | 181,381 | |
Cash and cash equivalents at end of period | $ | 223,771 | | | $ | 210,975 | |
| | | |
Supplemental cash flow information | | | |
Cash paid for interest on convertible notes | $ | 1,258 | | | $ | 1,258 | |
Cash paid for income taxes | 20,696 | | | 607 | |
Cash paid for operating leases | 4,036 | | | 1,991 | |
| | | |
Noncash investing and financing activities | | | |
Contingent consideration liability accrued in USWM Acquisition | $ | — | | | $ | 115,700 | |
Lease assets obtained for new leases | $ | 284 | | | $ | 24,738 | |
Deferred legal fees and fixed assets included in accounts payable and accrued expenses | $ | — | | | $ | 365 | |
See accompanying notes.
Supernus Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements (unaudited)
1. Business Organization
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. The Company is also developing a broad range of novel CNS product candidates including new potential treatments for ADHD, hypomobility in PD, epilepsy, depression, and rare CNS disorders.
Commercial Products
•Trokendi XR® (topiramate) is the first once-daily extended release topiramate product indicated for the treatment of epilepsy in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache.
•Oxtellar XR® (oxcarbazepine) is indicated as therapy for partial onset seizures in adults and children 6 years to 17 years of age and is the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.
•QelbreeTM (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in pediatric patients 6 to 17 years of age.
•APOKYN® (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility or "off" episodes ("end-of-dose wearing off" and unpredictable "on-off" episodes) in patients with advanced PD.
•MYOBLOC® (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults, and it is the only Type B toxin available on the market.
•XADAGO® (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.
Product Candidates
•SPN-812 (viloxazine hydrochloride) is a novel non-stimulant product candidate for the treatment of ADHD in adult patients.
•SPN-830 (Apomorphine Infusion Pump) is a late-stage drug/device combination product candidate for the continuous prevention of "off" episodes in PD.
•SPN-817 is a novel product candidate for the treatment of severe epilepsy.
•SPN-820 is a first-in-class product candidate for treatment resistant depression (TRD). It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).
In April 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree (SPN-812) for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree in the U.S.
On April 28, 2020, the Company entered into a Sale and Purchase Agreement with US WorldMeds Partners, LLC to acquire the CNS portfolio of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). With the acquisition, completed on June 9, 2020, the Company added three established commercial products, APOKYN, XADAGO, and MYOBLOC, and a product candidate in late-stage development, SPN-830, to its portfolio. Refer to Note 3, USWM Acquisition, for further discussion on the USWM Acquisition.
On April 21, 2020, the Company entered into a Development and Option Agreement (Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.) and also acquired an ownership position in Navitor Inc. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) in TRD. In March 2021, Navitor Inc. underwent a legal restructuring whereby Navitor Inc. became a wholly owned subsidiary of
a newly formed limited liability company, Navitor Pharmaceuticals, LLC (Navitor LLC). Refer to Note 5, Investments, for further discussion on the Navitor Development Agreement and equity investment.
COVID-19 Impact
While the impact of the ongoing COVID-19 pandemic did not have a material adverse effect on the Company's financial position or results of operations for the three and six months ended June 30, 2021, the Company continues to closely monitor the events and circumstances surrounding the COVID-19 pandemic and its impact on all aspects of our business operations. Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.
2. Summary of Significant Accounting Policies
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2020, filed with the SEC.
In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Reclassifications
Certain prior year amounts in the condensed consolidated statements of cash flows have been reclassified to conform to the current year condensed financial statement presentation. These reclassifications had no effect on operating cash flows or on our other condensed consolidated financial statements for the three and six months ended June 30, 2021 and 2020.
Consolidation
The Company’s condensed consolidated financial statements include those of the Company's wholly-owned subsidiaries and variable interest entities (VIE) where the Company is the primary beneficiary, if any. All significant intercompany transactions and balances have been eliminated in consolidation.
The Company continuously assesses whether it is the primary beneficiary of a VIE, as changes to existing relationships or future transactions may affect its conclusions.
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the creditworthiness of customers entering into revenue arrangements, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as printed materials and digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.
The Company incurred approximately $21.8 million and $37.1 million in advertising expense for the three and six months ended June 30, 2021, respectively, and approximately $10.9 million and $22.5 million for the three and six months ended June 30, 2020, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the condensed consolidated statements of earnings.
Recently Issued Accounting Pronouncements
Accounting Pronouncements Adopted
ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes - The new standard, issued in December 2019, simplifies the accounting for income taxes. The Company adopted the guidance on January 1, 2021, on a prospective basis. The adoption of the new standard did not have a material impact to the financial statements.
ASU 2020-01, Investments — Equity Securities (Topic 321), Investments — Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 - The new standard, issued in January 2020, clarifies the interaction of the equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain contracts and purchased options accounted for under Topic 815. The amendment clarifies that an entity can elect to adopt the measurement alternative, which is if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it should measure the equity security at fair value as of the date that the observable transaction occurred before applying or upon discontinuing the equity method. The adoption of the new standard as of January 1, 2021 did not have a material impact to the financial statements.
New Accounting Pronouncements Not Yet Adopted
ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity - The new standard, issued in August 2020, simplifies the accounting and disclosures for convertible instruments and contracts. This guidance will be effective on January 1, 2022 on a prospective basis. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.
3. USWM Acquisition
On June 9, 2020 (the Closing Date), the Company completed its acquisition of all of the outstanding equity of USWM Enterprises, a privately-held biopharmaceutical company, pursuant to a Sale and Purchase Agreement with US WorldMeds Partners, LLC (Seller), dated April 28, 2020 (the Agreement). Under the terms of the Agreement, the Company acquired the right to further develop and commercialize APOKYN, XADAGO, and the Apomorphine Infusion Pump (SPN-830; the In Process Research and Development (IPR&D) asset) in the U.S. and MYOBLOC worldwide (the Products) for an upfront cash payment of $297.2 million, subject to working capital adjustments, and the potential for additional contingent consideration payments of up to $230 million.
The potential $230 million in contingent consideration payments includes up to $130 million for the achievement of certain SPN-830 regulatory and commercial activities (regulatory and developmental contingent consideration payments) and up to $100 million related to future sales performance of the Products (sales-based contingent consideration payments). The regulatory and developmental contingent consideration payments include a $25 million milestone due upon the FDA's acceptance of the SPN-830 New Drug Application (NDA) for review. The remaining $105 million of the $130 million regulatory and developmental contingent consideration includes payments upon the FDA's regulatory approval and subsequent commercial launch by the Company of SPN-830, if approved. One of the regulatory milestones has a time-based mechanism for full or partial achievement. The $100 million sales-based contingent consideration payments include a $35 million milestone due upon achievement of certain U.S. net product sales of APOKYN during 2021. The remaining $65 million of the $100 million sales-based contingent consideration payments relate to the achievement of certain net product sales of the Products in 2022 and 2023. Refer to “Contingent Consideration” section below for further discussion.
In the second quarter of 2021 and within one year from the Closing Date, the Company finalized its accounting for the business combination, including the purchase price allocation; the Company recorded measurement period adjustments related to the purchase price consideration, finalization of the accounting for the lease (refer to Note 12, Leases), the fair values of inventory and intangible assets, and deferred tax liabilities based on refinements to inputs used in the estimates.
Purchase Price Consideration
The following table summarizes the purchase price consideration (unaudited):
| | | | | | | | | | | | | | | | | |
| As Initially Reported | | Measurement Period Adjustments (1) | | As Adjusted |
Cash consideration | $ | 304,194 | | | $ | 2,291 | | | $ | 306,485 | |
Estimated fair value of contingent consideration | 115,700 | | | (40,900) | | | 74,800 | |
Estimated total purchase consideration | $ | 419,894 | | | $ | (38,609) | | | $ | 381,285 | |
| | | | | |
Cash consideration to Seller - net of cash acquired | $ | 297,200 | | | $ | 2,291 | | | $ | 299,491 | |
______________________________(1) Measurement period adjustments reflect additional payments to Seller following the Closing Date for working capital adjustments on the purchase price consistent with the Agreement and an adjustment to the initial estimate of fair value of the contingent consideration.
The Company paid the Seller $297.2 million in cash at the Closing Date. From the Closing Date through the end of the measurement period, the Company incurred additional cash payments to Seller totaling $2.3 million for working capital adjustments on the purchase price consistent with the Agreement resulting in an increase to the original cash consideration paid to the Seller. Of the $2.3 million additional payments, $1.0 million was incurred in the second quarter of 2021 and the remainder was reported and paid in 2020.
Contingent Consideration
In addition to the cash paid to the Seller, contingent payments of up to $230 million are also due to the Seller upon the achievement of certain milestones related to the development of SPN-830 and sale of the Products. The possible outcomes for the contingent consideration range from $0, if no milestone is achieved, to $230 million on an undiscounted basis if all milestones are achieved.
The Company initially recorded a contingent consideration liability of $115.7 million as of the Closing Date to reflect the estimated fair value of the contingent consideration based on information available at that time. The estimated fair value of the contingent consideration was determined using a Monte Carlo simulation for the sales-based contingent consideration payments and an income approach for the regulatory and developmental contingent consideration payments. The key assumptions considered in estimating the fair value include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval, discount rate, the estimated revenue volatility and the estimated amount and timing of projected revenues from the Products. Subsequent to the Closing Date, the Company adjusted the contingent consideration fair value based on new information related to the facts and circumstances that existed as of the acquisition date related to the timing of meeting the conditions of the milestone payments that are contingent upon regulatory approval and commercial launch of the acquired IPR&D asset as well as the estimated timing of projected revenues from the Products. As a result, the Company recorded in the fourth quarter of 2020, a measurement period adjustment of $40.9 million, which decreased the estimated fair value of the contingent consideration liability as of Closing Date to $74.8 million. Refer to contingent consideration discussion in Note 6, Fair Value of Financial Instruments.
Fair Value of Net Assets Acquired
The following table presents the Company’s estimates of the fair value of the assets acquired and liabilities assumed as of the Closing Date, and subsequent measurement period adjustments recorded (unaudited, dollars in thousands):
| | | | | | | | | | | | | | | | | |
| As Initially Reported | | Measurement Period Adjustments (1) | | As Adjusted |
Cash and cash equivalents | $ | 6,994 | | | $ | — | | | $ | 6,994 | |
Accounts receivable, net | 18,474 | | | — | | | 18,474 | |
Inventories, net (2) | 10,400 | | | 1,200 | | | 11,600 | |
Prepaid expenses and other current assets | 3,564 | | | — | | | 3,564 | |
Property and equipment, net | 454 | | | — | | | 454 | |
Finance lease asset (3) | 22,747 | | | (22,747) | | | — | |
Operating lease asset (3) | — | | | 11,029 | | | 11,029 | |
Intangible assets (4) | 387,000 | | | (32,000) | | | 355,000 | |
Other assets | 340 | | | — | | | 340 | |
Total fair value of assets acquired | 449,973 | | | (42,518) | | | 407,455 | |
Accounts payable | (2,573) | | | — | | | (2,573) | |
Accrued expenses and other current liabilities | (23,339) | | | — | | | (23,339) | |
Finance lease liability (3) | (22,747) | | | 22,747 | | | — | |
Operating lease liability (3) | — | | | (11,029) | | | (11,029) | |
Deferred income tax liabilities, net (5) | (69,515) | | | 2,323 | | | (67,192) | |
Total fair value of liabilities assumed | (118,174) | | | 14,041 | | | (104,133) | |
Total identifiable net assets | $ | 331,799 | | | $ | (28,477) | | | $ | 303,322 | |
Goodwill | 88,095 | | | (10,132) | | | 77,963 | |
Total purchase price (6) | $ | 419,894 | | | $ | (38,609) | | | $ | 381,285 | |
______________________________
(1) Measurement period adjustments reflect adjustments based on information related to the facts and circumstances that existed as of the acquisition date.
(2) Refer to discussion on Acquired Inventory below for measurement period adjustments to inventory.
(3) Refer to Note 12, Leases, for further discussion of the acquired lease asset and assumed lease liability.
(4) Refer to discussion on Acquired Intangible Assets below for measurement period adjustments to intangible assets.
(5) Includes tax attributes that are subject to tax limitations. Measurement period adjustment is primarily due to the tax impact of the changes in the initial estimate of the fair value of intangible assets and inventories and estimates of tax attributes and positions.
(6) Measurement period adjustments include an adjustment to the fair value of the contingent consideration net of the additional cash payment made to the Seller.
Acquired Inventory
The estimated fair value of the inventory was determined using the comparative sales method, which estimated the expected sales price of the product, reduced by all costs expected to be incurred to complete or to dispose of the inventory, as well as a profit on the sale. The Company recorded a total measurement adjustment of $1.2 million consisting of a $1.9 million adjustment in the second quarter of 2021 due to refinements to inputs and assumptions related to the costs to dispose, offset by a $0.7 million adjustment recorded in the fourth quarter of 2020 due to refinements to the inputs and assumptions pertaining to the estimate of acquired inventories' obsolescence based on review of product dating information.
Acquired Intangible Assets
The acquired intangible assets include the acquired IPR&D asset and the acquired developed technology and product rights. The Company determined the estimated fair value of the acquired intangible assets as of the Closing Date using the income approach. The fair value measurements of the acquired intangible assets were determined based on significant unobservable inputs and therefore, represent a Level 3 fair value measurement. Some of the more significant inputs and assumptions used in the
intangible assets valuation include: the timing and probability of success of clinical and regulatory approvals for the IPR&D asset, the estimated future cash flows from Product sales, the timing and projection of costs and expenses, discount rates and tax rates.
The Company initially recorded a fair value of intangible assets of $387 million, which consisted of $150 million related to the acquired IPR&D and $237 million related to acquired developed technology and Product rights. The initial estimate of the fair value of intangible assets recorded as of the Closing Date is based on information available at that time. In the fourth quarter of 2020, the Company recorded measurement period adjustments of $32 million, which adjusted the initial estimated fair value of the intangible assets to $355 million as of the Closing Date. The revisions were based on updated assumptions and information related to the facts and circumstances that existed as of the acquisition date. The Company updated assumptions with respect to the timing of regulatory approval and the commercialization of the acquired IPR&D asset. In addition, the Company also made refinements of the estimates of projected cash flows based on review of terms of the contractual arrangements associated with the acquired Products.
In the second quarter of 2021, the Company made further refinements to its estimates of projected cash flows based on review of Product costs and expense inputs which resulted in an increase to the fair value of the IPR&D asset of $1 million and an offsetting decrease in the fair value of the acquired developed technology and products rights of $1 million. The total estimated fair value of the intangible assets as of the Closing Date, and as of June 30, 2021, remained at $355 million.
The following table summarizes the purchase price allocation, and the average remaining useful lives for identifiable intangible assets (unaudited, dollars in thousands):
| | | | | | | | | | | |
| Estimated Fair Value | | Estimated Useful Lives as of Closing Date (in years) |
Acquired IPR&D | $ | 124,000 | | | n/a |
Acquired developed technology and product rights | 231,000 | | | 10.5 - 12.5 |
Total intangible assets | $ | 355,000 | | | |
Acquired intangible assets, excluding the acquired IPR&D asset, are amortized over their estimated useful lives on a straight-line basis. The IPR&D asset is considered indefinite-lived, until the successful completion or abandonment of the associated research and development efforts.
Goodwill
Goodwill was calculated as the excess of the consideration paid consequent to completing the acquisition, compared to the net assets recognized. Goodwill represents the future economic benefits from the other acquired assets, and which could not be individually identified and separately valued. Goodwill is primarily attributable to the additional acquired growth platforms and an expanded revenue base. Goodwill is not deductible for tax purposes.
Pro forma Information
The following table presents the unaudited pro forma combined financial information as if the USWM Acquisition had occurred on January 1, 2019 (dollars in thousands):
| | | | | | | | | | | |
| Three Months ended June 30, 2020 | | Six Months ended June 30, 2020 |
Pro forma total revenues | $ | 151,803 | | | $ | 284,965 | |
Pro forma net earnings | 39,220 | | | 62,700 | |
The unaudited pro forma combined financial information is based on historical financial information as well the Company’s allocation of the purchase price. In order to reflect the occurrence of the acquisition as if it occurred on January 1, 2019, the unaudited pro forma combined financial information reflects the adoption of ASC 842, Leases; the recognition of additional amortization expense on intangible assets, the removal of historical amortization charges and the elimination of non-recurring acquisition-related transaction costs.
The unaudited pro forma combined financial information should not be considered indicative of the results that would have occurred if the acquisition had been consummated on the assumed completion date, nor are they indicative of future results.
4. Disaggregated Revenues
The following table summarizes the disaggregation of revenues by product or source, (dollars in thousands): | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months ended June 30, | | Six Months ended June 30, |
| 2021 | | 2020 | | 2021 | | 2020 |
| (unaudited) | | (unaudited) |
Net product sales | | | | | | | |
Trokendi XR | $ | 78,777 | | | $ | 89,674 | | | $ | 150,596 | | | $ | 158,225 | |
Oxtellar XR | 25,022 | | | 23,680 | | | 52,392 | | | 47,619 | |
APOKYN | 26,981 | | | 8,600 | | | 48,711 | | | 8,600 | |
MYOBLOC (1) | 4,641 | | | 1,229 | | | 8,881 | | | 1,229 | |
XADAGO | 2,892 | | | 801 | | | 6,114 | | | 801 | |
Qelbree | 315 | | | — | | | 315 | | | — | |
Total net product sales | $ | 138,628 | | | $ | 123,984 | | | $ | 267,009 | | | $ | 216,474 | |
Royalty revenues | 2,701 | | | 2,745 | | | 5,252 | | | 5,231 | |
Total revenues | $ | 141,329 | | | $ | 126,729 | | | $ | 272,261 | | | $ | 221,705 | |
______________________________
(1) In April 2021, the Company notified the European Medicine Agency that it will cease the marketing of rimabotulinumtoxinB in European countries where it has been marketed as NeuroBloc.
Trokendi XR accounted for 57% and 56% of the Company’s total net product sales for the three and six months ended, June 30, 2021, respectively, and approximately 73% of the Company's total net product sales for both the three and six months ended, June 30, 2020.
The Company's three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 25% of our total net product sales and collectively accounted for more than 85% of our total net product sales in both 2021 and 2020.
The Company recognized noncash royalty revenue of $2.2 million and $4.4 million, for the three and six months ended June 30, 2021, respectively. The Company recognized noncash royalty revenue of $2.3 million and $3.9 million, for the three and six months ended June 30, 2020, respectively. Refer to Note 15, Commitments and Contingencies.
5. Investments
Marketable Securities
Unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands): | | | | | | | | | | | |
| June 30, 2021 | | December 31, 2020 |
| (unaudited) | | |
Amortized cost | $ | 624,324 | | | $ | 472,306 | |
Gross unrealized gains | 7,512 | | | 11,987 | |
Gross unrealized losses | (293) | | | (41) | |
Total fair value | $ | 631,543 | | | $ | 484,252 | |
The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands): | | | | | |
| June 30, 2021 |
| (unaudited) |
Less than 1 year | $ | 186,070 | |
1 year to 2 years | 202,969 | |
2 years to 3 years | 211,603 | |
3 years to 4 years | 30,901 | |
Greater than 4 years | — | |
Total | $ | 631,543 | |
As of June 30, 2021, there was no impairment due to credit loss on any available-for-sale marketable securities.
Investment in Navitor
Development and Option agreement
In April 2020, the Company entered into the Development Agreement with Navitor Inc. The Company can terminate the Development Agreement upon 30 days’ notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) for TRD. The Company will bear all of the Phase I and Phase II development costs incurred by either party, up to a maximum of $50 million. In addition, the Company will incur certain other research and development support costs. There are certain additional payment amounts which could be incurred by the Company. These costs are contingent upon Navitor Inc. achieving defined development milestones. The Company has an option to acquire or license NV-5138 (SPN-820), for which additional payments would be required. In the second quarter of 2020, the Company paid Navitor Inc. a one time, nonrefundable, and non-creditable fee of $10 million for this option to acquire or license NV-5138 (SPN-820).
Equity investment
In addition to entering into the Development Agreement in April 2020, the Company acquired Series D Preferred Shares of Navitor Inc. for $15 million, representing an approximately 13% ownership position in Navitor Inc.
In March 2021, Navitor Inc. underwent a legal restructuring. In the restructuring, Navitor Inc. became a wholly owned subsidiary of a newly formed limited liability company, Navitor LLC, and the outstanding shares of stock in Navitor Inc. were exchanged for units of membership interest in Navitor LLC having equivalent rights and preferences (Navitor Restructuring). As part of the Navitor Restructuring, the Series D Preferred Shares previously held by the Company were exchanged for Series D Preferred Units in Navitor LLC. In addition, certain assets that did not relate to NV-5138 (SPN-820) were transferred from Navitor Inc. to a newly formed entity that became a separate, wholly owned subsidiary of Navitor LLC.
The Company had determined that Navitor LLC is a VIE. The Company does not consolidate this VIE because the Company lacks the power to direct the activities that most significantly impact the investee’s economic performance.
Prior to the Navitor Restructuring, the investment was accounted for under the practical expedient allowed for equity securities without readily determinable fair value, which is cost minus impairment plus any changes in observable price changes from an orderly transaction of similar investments in Navitor Inc. Following the legal restructuring and exchange of the preferred shares for member equity units of Navitor LLC, the investment was accounted for under the equity method of accounting due to the Company’s ability to exert significant influence, but not control the financial and operating decisions. The majority of the assets and liabilities recorded in Navitor LLC’s financial statements represent working capital items and cash that are being used for research and development purposes and are significantly lower than the Company’s investment in Navitor LLC. This created a significant basis difference for the Company’s investment in the underlying net assets, requiring the Company to account for the investee as if it were a consolidated subsidiary in a manner consistent with the provisions of ASC 805, Business Combinations, to apply the acquisition method of accounting. The Company has determined that substantially all of the fair value of the investment is attributable to a single IPR&D asset. As a result, the investee is not considered a business as defined in ASC 805. In the first quarter of 2021, the $15 million investment, which was previously recorded in Other assets in the condensed consolidated balance sheets, was expensed and recorded in Research and development expense in the condensed consolidated statements of earnings.
The maximum exposure to losses related to the investee is a maximum of approximately $50 million in expense for Phase I and Phase II development of NV-5138 (SPN-820), and the cost of other development and formulation activities provided by the Company.
The Company has provided no financing to the investee other than amounts required under the Development Agreement.
6. Fair Value of Financial Instruments and Contingent Consideration
The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.
The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. Fair value hierarchy consists of the following three levels:
•Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets.
•Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves).
•Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data.
The fair value of the restricted marketable securities which are classified as level 2 financial assets is recorded in Other assets on the condensed consolidated balance sheets. There were no level 3 financial assets as of June 30, 2021 or December 31, 2020. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.
Financial Assets and Liabilities Recorded at Fair Value on a Recurring Basis
The Company’s financial assets that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands): | | | | | | | | | | | | | | | | | | | | | | | |
| | | Fair Value Measurements at June 30, 2021 (unaudited) |
| Total Fair Value at June 30, 2021 | | Level 1 | | Level 2 | | Level 3 |
Assets: | | | | | | | |
Cash and cash equivalents | | | | | | | |
Cash | $ | 200,493 | | | $ | 200,493 | | | $ | — | | | $ | — | |
Money market funds | 23,278 | | | 23,278 | | | — | | | — | |
Marketable securities | | | | | | | |
Corporate debt securities | 183,944 | | | 253 | | | 183,691 | | | — | |
Municipal debt securities | 2,126 | | | — | | | 2,126 | | | |
Long term marketable securities | | | | | | | |
Corporate debt securities | 445,473 | | | — | | | 445,473 | | | — | |
| | | | | | | |
Other noncurrent assets | | | | | | | |
Marketable securities - restricted (SERP) | 604 | | | 5 | | | 599 | | | — | |
Total assets at fair value | $ | 855,918 | | | $ | 224,029 | | | $ | 631,889 | | | $ | — | |
Liabilities: | | | | | | | |
Contingent consideration | $ | 68,970 | | | $ | — | | | $ | — | | | $ | 68,970 | |
Total liabilities at fair value | $ | 68,970 | | | $ | — | | | $ | — | | | $ | 68,970 | |
| | | | | | | | | | | | | | | | | | | | | | | |
| | | Fair Value Measurements at December 31, 2020 |
| Total Fair Value at December 31, 2020 | | Level 1 | | Level 2 | | Level 3 |
Assets: | | | | | | | |
Cash and cash equivalents | | | | | | | |
Cash | $ | 218,550 | | | $ | 218,550 | | | $ | — | | | $ | — | |
Money market funds | 70,090 | | | 70,090 | | | — | | | — | |
Marketable securities | | | | | | | |
Corporate debt securities | 133,893 | | | — | | | 133,893 | | | — | |
Long term marketable securities | | | | | | | |
Corporate debt securities | 350,359 | | | 256 | | | 350,103 | | | — | |
Other noncurrent assets | | | | | | | |
Marketable securities - restricted (SERP) | 547 | | | 3 | | | 544 | | | — | |
Total assets at fair value | $ | 773,439 | | | $ | 288,899 | | | $ | 484,540 | | | $ | — | |
Liabilities: | | | | | | | |
Contingent consideration | $ | 76,700 | | | $ | — | | | $ | — | | | 76,700 | |
Total liabilities at fair value | $ | 76,700 | | | $ | — | | | $ | — | | | $ | 76,700 | |
Other Financial Instruments
The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses, approximate fair value due to their short-term maturities.
The Company records its convertible debt at carrying value. The fair value of the outstanding convertible debt is based on actual trading information as well as quoted prices, both provided by bond traders. Refer to Note 8, Convertible Senior Notes Due 2023.
The Company also had an investment in Navitor LLC, a privately held company, which it classifies as Level 3 as it does not have a readily determinable fair value. In the first quarter of 2021, the $15 million investment in Navitor LLC was expensed. Refer to Note 5, Investments.
Contingent Consideration
The contingent consideration liabilities are measured at fair value on a recurring basis. In the fourth quarter of 2020, the Company recorded a measurement period adjustment of $40.9 million. Refer to Note 3, USWM Acquisition. In the second quarter of 2021, the Company recorded a change in fair value of $7.7 million, which is primarily due to the write-down of the sales based contingent consideration liabilities offset by an increase in the estimated fair value of regulatory and developmental milestones due to passage of time. The Company assessed that these sales-based milestones will not be achieved based on the revised net sales projections. The probability of achieving these milestones were significantly lower compared to prior estimates. The Company updated its projected net sales of the Products based on recent historical sales trend experience.
The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and composition of the contingent consideration liabilities (dollars in thousands):
| | | | | | | | |
| | Balance |
Initial measurement at Closing Date at June 9, 2020 | | 115,700 | |
Measurement period adjustment | | (40,900) | |
Change in fair value recognized in earnings | | 1,900 | |
Balance at December 31, 2020 | | $ | 76,700 | |
| | |
Balance at December 31, 2020 | | $ | 76,700 | |
Change in fair value recognized in earnings (unaudited) | | (7,730) | |
Balance at June 30, 2021 (unaudited) | | $ | 68,970 | |
| | |
| June 30, 2021 | December 31, 2020 |
| (unaudited) | |
Regulatory and developmental contingent consideration liabilities | $ | 68,970 | | $ | 68,000 | |
Sales-based contingent consideration liabilities | — | | 8,700 | |
Total | $ | 68,970 | | $ | 76,700 | |
7. Goodwill and Intangible Assets, Net
The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets and goodwill (dollars in thousands): | | | | | | | | | | | | | | | | | |
| Remaining Weighted- Average Life (Years) | | June 30, 2021 | | December 31, 2020 |
| (unaudited) |
Goodwill | | | $ | 77,963 | | | $ | 77,911 | |
| | | | | |
Intangible assets: | | | | | |
Acquired IPR&D | | | $ | 124,000 | | | $ | 123,000 | |
Definite-lived intangible assets | | | | | |
Acquired developed technology and product rights | 9.50 - 11.50 | | 231,000 | | | 232,000 | |
Capitalized patent defense costs | 1.50 - 5.75 | | 43,820 | | | 43,579 | |
| | | 398,820 | | | 398,579 | |
Less accumulated amortization | | | (46,192) | | | (34,237) | |
Total intangible assets, net | | | $ | 352,628 | | | $ | 364,342 | |
The increase in goodwill represents measurement period adjustments recorded in 2021 related to the finalization of the business combination accounting of the USWM Acquisition. Refer to Note 3, USWM Acquisition.
Patent defense costs are deferred legal fees incurred in conjunction with defending patents for Oxtellar XR and Trokendi XR. U.S. patents covering Oxtellar XR and Trokendi XR will expire no earlier than 2027. In regard to Trokendi XR, the Company entered into settlement agreements that allow third parties to enter the market by January 1, 2023, or earlier under certain circumstances.
Amortization expense for intangible assets was approximately $5.9 million and $12.0 million for the three and six months ended June 30, 2021, respectively, and approximately $2.4 million and $3.7 million for the three and six months ended June 30, 2020, respectively. The increase in expense is due to amortization of the acquired developed technology and product rights from the USWM Acquisition.
8. Convertible Senior Notes Due 2023
The 0.625% Convertible Senior Notes Due 2023 (2023 Notes), which were issued in March 2018, bear interest at an annual rate of 0.625%, payable semi-annually in arrears on April 1 and October 1 of each year. The 2023 Notes will mature on April 1, 2023, unless earlier converted or repurchased by the Company. The Company may not redeem the 2023 Notes at its option before maturity. The total principal amount of 2023 Notes is $402.5 million.
The 2023 Notes were issued pursuant to an Indenture between the Company and Wilmington Trust, National Association, as trustee. The Indenture includes customary terms and covenants, including certain events of default upon which the 2023 Notes may be due and payable immediately. The Indenture does not contain any financial or operating covenants, or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.
Noteholders may convert their 2023 Notes at their option only in the following circumstances: (1) during any calendar quarter, if the last reported sale price per share of the Company's common stock for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including the last trading day of the immediately preceding calendar quarter, exceeds 130% of the conversion price, or a price of approximately $77.13 per share on such trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the "measurement period") in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company's common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company's common stock, as specified in the Indenture; and (4) at any time from and including October 1, 2022, until the close of business on the second scheduled trading day immediately before the maturity date.
At its election, the Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, based on the applicable conversion rate. The initial conversion rate is 16.8545 shares per $1,000 principal amount of the 2023 Notes, which represents an initial conversion price of approximately $59.33 per share, and is subject to adjustment as specified in the Indenture. In the event of conversion, if converted in cash, the holders would forgo all future interest payments, any unpaid accrued interest, and the possibility of further stock price appreciation.
If a “make-whole fundamental change,” as defined in the Indenture occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time. If a “fundamental change,” as defined in the Indenture occurs, then noteholders may require the Company to repurchase their 2023 Notes at a cash repurchase price equal to the principal amount of the 2023 Notes to be repurchased, plus accrued and unpaid interest, if any.
Contemporaneous with the issuance of the 2023 Notes, the Company also entered into separate privately negotiated convertible note hedge transactions (collectively, the Convertible Note Hedge Transactions) with each of the call spread counterparties. The Company issued 402,500 convertible note hedge options. In the event that shares or cash are deliverable to holders of the 2023 Notes upon conversion at limits defined in the Indenture, counterparties to the convertible note hedges will be required to deliver up to approximately 6.8 million shares of the Company’s common stock, or to pay cash to the Company in a similar amount as the value that the Company delivers to the holders of the 2023 Notes, based on a conversion price of $59.33 per share.
Concurrently with entering into the Convertible Note Hedge Transactions, the Company also entered into separate privately negotiated warrant transactions (collectively, the Warrant Transactions) with each of the call spread counterparties. The Company issued a total of 6,783,939 warrants. The warrants entitle the holder to one share per warrant. The strike price of the Warrant Transactions will initially be $80.9063 per share of the Company’s common stock, and is subject to adjustment.
The Convertible Note Hedge Transactions are expected to reduce the potential dilution of the Company’s common stock upon conversion of the 2023 Notes, and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2023 Notes, as the case may be.
The Warrant Transactions were intended to partially offset the cost to the Company of the purchased Convertible Note Hedge Transactions; however, the Warrant Transactions could have a dilutive effect with respect to the Company’s common stock, to the extent that the market price per share of the Company’s common stock, as measured under the terms of the Warrant Transactions, exceeds the strike price of the warrants.
The liability component of the 2023 Notes consists of the following, (dollars in thousands): | | | | | | | | | | | |
| June 30, 2021 | | December 31, 2020 |
| (unaudited) | | |
2023 Notes | $ | 402,500 | | | $ | 402,500 | |
Unamortized debt discount and deferred financing costs | (32,117) | | | (40,749) | |
Total carrying value | $ | 370,383 | | | $ | 361,751 | |
| | | |
Fair value (Level 2) | $ | 398,727 | | | $ | 383,381 | |
No 2023 Notes were converted as of June 30, 2021 or December 31, 2020.
9. Share-Based Payments
Share-based compensation expense is as follows (dollars in thousands): | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months ended June 30, | | Six Months ended June 30, |
| 2021 | | 2020 | | 2021 | | 2020 |
| (unaudited) | | (unaudited) |
Research and development | $ | 706 | | | $ | 818 | | | $ | 1,294 | | | $ | 1,499 | |
Selling, general and administrative | 4,770 | | | |